0000000000721846

AUTHOR

Bernard Erdtracht

showing 2 related works from this author

Rheopheresis in Patients with Critical Limb Ischemia--Results of an Open Label Prospective Pilot Trial

2005

Rheopheresis is a specifically designed application of double filtration plasmapheresis, for extracorporeal treatment of microcirculatory disorders. Safety and efficacy of Rheopheresis for wound healing and skin oxygenation were investigated in patients with critical limb ischemia. Twelve patients of Fontaine stage III-IV were treated with a series of 10 Rheopheresis sessions over 17 weeks. Transcutaneous oxygen pressure (tcpO(2)) and ankle-brachial index (ABI) were repeatedly determined to monitor the effects of the Rheopheresis treatment series on microcirculation and skin blood flow. Laboratory parameters of blood rheology were measured in addition to safety parameters and course of the …

Malemedicine.medical_specialtymedicine.medical_treatmentRheopheresisPilot ProjectsExtracorporealMicrocirculationIschemiamedicineHumansalpha-MacroglobulinsProspective StudiesProspective cohort studyAgedSkinWound Healingbusiness.industryFibrinogenProteinsCholesterol LDLPlasmapheresisHematologyCritical limb ischemiaOxygenationMiddle AgedSurgeryClinical trialTreatment OutcomeImmunoglobulin MLower ExtremityAmputationRegional Blood FlowNephrologyFemalemedicine.symptombusinessBlood Gas Monitoring TranscutaneousTherapeutic Apheresis and Dialysis
researchProduct

RheoNet Registry Analysis of Rheopheresis for Microcirculatory Disorders With a Focus on Age-Related Macular Degeneration

2010

The purpose of establishing the RheoNet registry was to evaluate the safety and efficacy of rheopheresis, a specific method of therapeutic apheresis used to treat microcirculatory disorders. Apheresis centers providing rheopheresis therapy and physicians caring for the underlying disease were asked to participate in the registry, and the registry data were analyzed for safety and tolerability. Age-related macular degeneration (AMD) was selected as a model disease to evaluate efficacy. The RheoNet registry was successfully established recording 7722 rheopheresis treatments of 1110 patients, including 833 AMD patients. The mean age of patients was 72 years. Adverse events (AE) were reported i…

medicine.medical_specialtyVisual acuitygenetic structuresbusiness.industryRheopheresisHematologyMacular degenerationmedicine.diseaseeye diseasesSurgeryApheresisTolerabilityNephrologyAge relatedInternal medicinemedicinemedicine.symptomAdverse effectbusinessTherapeutic apheresisTherapeutic Apheresis and Dialysis
researchProduct